Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.11 EUR
−33.05 M EUR
12.13 M EUR
156.23 M
About NYKODE THERAPEUTICS ASA
Sector
CEO
Michael Thyrring Engsig
Headquarters
Oslo
Website
Founded
2006
ISIN
NO0010714785
FIGI
BBG00XZ9Z9B9
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. It focuses on developing field of individualized cancer neoantigen vaccines by using the Vaccibody technology to generate therapeutics to treat cancer. The company was founded by Inger Sandlie and Agnete Brunsvik Fredriksen on November 22, 2006 and is headquartered in Oslo, Norway.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 5VB is 0.20 EUR — it has increased by 1.56% in the past 24 hours. Watch NYKODE THERAPEUTICS ASA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange NYKODE THERAPEUTICS ASA stocks are traded under the ticker 5VB.
5VB stock has risen by 24.57% compared to the previous week, the month change is a −47.58% fall, over the last year NYKODE THERAPEUTICS ASA has showed a −87.90% decrease.
We've gathered analysts' opinions on NYKODE THERAPEUTICS ASA future price: according to them, 5VB price has a max estimate of 4.43 EUR and a min estimate of 0.22 EUR. Watch 5VB chart and read a more detailed NYKODE THERAPEUTICS ASA stock forecast: see what analysts think of NYKODE THERAPEUTICS ASA and suggest that you do with its stocks.
5VB stock is 10.88% volatile and has beta coefficient of 2.47. Track NYKODE THERAPEUTICS ASA stock price on the chart and check out the list of the most volatile stocks — is NYKODE THERAPEUTICS ASA there?
Today NYKODE THERAPEUTICS ASA has the market capitalization of 70.88 M, it has increased by 21.85% over the last week.
Yes, you can track NYKODE THERAPEUTICS ASA financials in yearly and quarterly reports right on TradingView.
NYKODE THERAPEUTICS ASA is going to release the next earnings report on Nov 27, 2024. Keep track of upcoming events with our Earnings Calendar.
5VB earnings for the last quarter are −0.02 EUR per share, whereas the estimation was −0.05 EUR resulting in a 54.22% surprise. The estimated earnings for the next quarter are −0.04 EUR per share. See more details about NYKODE THERAPEUTICS ASA earnings.
NYKODE THERAPEUTICS ASA revenue for the last quarter amounts to 517.06 K EUR, despite the estimated figure of 3.69 M EUR. In the next quarter, revenue is expected to reach 2.62 M EUR.
5VB net income for the last quarter is −6.94 M EUR, while the quarter before that showed −13.46 M EUR of net income which accounts for 48.43% change. Track more NYKODE THERAPEUTICS ASA financial stats to get the full picture.
No, 5VB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 27, 2024, the company has 173.00 employees. See our rating of the largest employees — is NYKODE THERAPEUTICS ASA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NYKODE THERAPEUTICS ASA EBITDA is −53.07 M EUR, and current EBITDA margin is −423.64%. See more stats in NYKODE THERAPEUTICS ASA financial statements.
Like other stocks, 5VB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NYKODE THERAPEUTICS ASA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NYKODE THERAPEUTICS ASA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NYKODE THERAPEUTICS ASA stock shows the sell signal. See more of NYKODE THERAPEUTICS ASA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.